BML Capital Management, LLC Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001616824

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 18 positions · Total reported value $176.05M · Top-10 concentration 93.3% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 38.1% · 3 new · 4 cut · 1 exited

Active Share (vs S&P 500): 99.2% · vs QQQ: 99.3% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): +2.1% · vs SPY -0.0% · Prev Value $176.05M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -15.2% · vs SPY -17.3% · Latest Value $187.62M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2026 13F filing, BML Capital Management, LLC disclosed 18 equity positions with a combined reported value of $176.05M. The filing implies a focused portfolio: its ten largest positions account for 93.3% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were ACRS ($63.35M), AVIR ($32.33M), ENGN ($11.54M). By sector, the heaviest allocations are Health Care 80.1%, Consumer Discretionary 13.3%. Versus the prior quarter, allocation shifted toward Consumer Staples (+4.4pp) and away from Health Care (-1.8pp), Other (-3.4pp).

Versus the prior quarter, BML Capital Management, LLC opened 3 new positions, trimmed 4 and fully exited 1, a turnover rate of 38.1% of positions. The portfolio's overlap with the prior quarter was 79% of names.

The largest new positions opened in Q2 2026 were ENGN ($11.54M), CORZ ($298.00K), TSLA ($270.00K).

Of the 1 positions fully exited versus the prior quarter, the largest were KZR ($5.35M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • ENGN ENGENE THERAPEUTICS INC · $11.54M
  • CORZ CORE SCIENTIFIC INC NEW · $298.00K
  • TSLA TESLA INC · $270.00K

Fully Exited (vs previous quarter)

  • KZR KEZAR LIFE SCIENCES INC · prev qtr: $5.35M

Insider Transactions (Form 4)

Latest BML Capital Management, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

BML Capital Management, LLC files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 18 positions worth $176.05M in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 18 positions · $176.05M reported value (Q2 2026)
  • Top 10 holdings = 93.3% of reported value
  • Largest position: ACRS (ACLARIS THERAPEUTICS INC) at 36.0%
  • Average position size: $9.78M

Sector Tilt

  • Health Care 80.1%
  • Consumer Discretionary 13.3%
  • Consumer Staples 6.2%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 3 new, 4 added, 3 reduced, 1 exited
  • 8 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: BML Capital Management appears to be taking a conservative approach with a focus on diversification. The reduction in positions and the cautious addition of new holdings suggest a preference for stability and risk management in a potentially uncertain market environment. 2. Key Moves: - Reduced Positions: The fund reduced holdings in ACLARIS THERAPEUTICS INC (-16.0% QoQ) and TEVA PHARMACEUTICAL IN F (-1.5% QoQ), indicating a preference for shedding riskier assets or seeking better opportunities elsewhere. - New Positions: The fund added ENGENE THERAPEUTICS INC, KRAFT HEINZ CO, and OUTSET MED INC, showing a willingness to explore new sectors and potentially benefit from growth opportunities. - Increased Positions: KRAFT HEINZ CO and OUTSET MED INC saw significant increases in share count, possibly indicating a belief in the long-term prospects of these companies. 3. Portfolio Structure: - Passive/Active: The fund appears to be leaning towards a passive strategy, as indicated by the "Hold" actions on most positions. - Sector Bias: The portfolio is heavily biased towards the Health Care sector, which accounts for over 40% of the total value. - Risk Appetite: The fund exhibits a moderate risk appetite, as seen by the addition of new holdings in sectors like Consumer Staples and Health Care, but with a preference for stability as evidenced by the reduction in some Health Care positions. 4. Per-Holding One-Liner: - ACRS: ACLARIS THERAPEUTICS INC - Developing therapies for neurological conditions, 'Reduce' - AVIR: TEVA PHARMACEUTICAL IN F - Global pharmaceutical company, 'Reduce' - ENGN: ENGENE THERAPEUTICS INC - Biotechnology company focusing on gene editing, 'New' - KHC: KRAFT HEINZ CO - Consumer goods manufacturer, 'Add' - OM: OUTSET MED INC - Biotechnology company focusing on drug discovery, 'Add' - KMX: CARMAX INC - Automotive retail and services, 'Add' - TLYS: TILLY'S INC CL A - Discount retailer, 'Hold' - PMVP: PMV PHARMACEUTICALS - Biotechnology company focused on drug development, 'Hold' - TIL: INSTIL BIO INC - Biotechnology company, 'Hold' - TGT: TARGET CORP - Retailer of general merchandise and food, 'Hold' - 'Unverified': None noted. 5. One-Sentence Style Summary: BML Capital Management's rebalancing in Q2 2026 demonstrates a cautious yet opportunistic approach, with a focus on diversifying its portfolio while maintaining a significant stake in the Health Care sector.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 80.1%
Financials 0.2%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 11.97M $63.35M 35.98%
35.98%
Reduce
2 6.95M $32.33M 18.36%
18.36%
Reduce
3 6.67M $11.54M 6.55%
6.55%
New
4 465.00K $10.98M 6.24%
6.24%
Add
5 2.52M $10.89M 6.18%
6.18%
Add
6 172.50K $9.12M 5.18%
5.18%
Add
7 2.15M $9.03M 5.13%
5.13%
Hold
8 5.33M $7.14M 4.06%
4.06%
Hold
9 645.60K $4.96M 2.82%
2.82%
Hold
10 37.50K $4.90M 2.78%
2.78%
Hold
11 866.27K $4.17M 2.37%
2.37%
Reduce
12 154.96K $2.38M 1.35%
1.35%
Hold
13 1.55M $1.76M 1.00%
1.00%
Hold
14 573.29K $1.36M 0.78%
0.78%
Add
15 200.73K $1.18M 0.67%
0.67%
Hold
16 335 $386.09K 0.22%
0.22%
Hold
17 800 $298.00K 0.17%
0.17%
New
18 375 $270.00K 0.15%
0.15%
New

FAQ

What did BML Capital Management, LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, BML Capital Management, LLC reported 18 equity positions worth $176.05M in aggregate; its largest disclosed positions were ACRS ($63.35M), AVIR ($32.33M), ENGN ($11.54M).

How large is BML Capital Management, LLC's portfolio?

BML Capital Management, LLC reported $176.05M of long equity holdings across 18 positions as of 2026-Q2. Top-10 holdings account for 93.3% of reported value.

What is BML Capital Management, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/bml-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →